Psilocybin
What you gain
A supported experience some bereaved people seek in research settings.
What it asks of you
Experimental evidence and self-pay.
Comparison guide
Psilocybin or Spravato for Grief
Neither has proven prolonged-grief trials. Spravato’s label is depression care, not grief care.
Answers at a glance
Comprehensive comparison
Psilocybin
Not established for prolonged grief.1
Spravato
Not established for grief — no grief indication on the label.3
Psilocybin
Not established.
Spravato
Not studied as grief care.
Psilocybin
Nothing daily to stop after a research-style course.
Spravato
Stopping follows depression maintenance rules, not a grief plan.
Psilocybin
Research pilots: prep, one dosing day, integration.2
Spravato
No grief protocol — prescribing follows depression visit rules.3
Psilocybin
Guided-session market rates if pursued as a legal experience.5
Spravato
Depression-clinic pricing — not sold as a grief package.
Psilocybin
Almost never.
Spravato
Only if billed as covered depression care — not for grief alone.3
Psilocybin
Not enough direct evidence yet.1
Spravato
Not studied for grief. Grief-focused talk therapy has far stronger support.34
References & sources
- 1Beesley et al. (2024). Psychedelics for prolonged grief — no finished large trials yet. View study →
- 2PARTING protocol (2025). Early psilocybin pilot for grief after cancer loss. View study →
- 3FDA. SPRAVATO labeled uses (depression). View study →
- 4Review pointing to grief-focused talk therapy for prolonged grief. View study →
- 5Oregon Health Authority. Accessing psilocybin services. View study →
Typical US ranges and outcomes; your care depends on screening and clinical need. Not medical advice.
Considerations
Every path has a trade
Spravato
What you gain
An FDA path when depression is the clinical target.
What it asks of you
No grief indication and no grief evidence base.